Private Asset Management Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 147,735 shares of the company’s stock after selling 995 shares during the period. Johnson & Johnson comprises 2.9% of Private Asset Management Inc.’s portfolio, making the stock its 6th largest position. Private Asset Management Inc.’s holdings in Johnson & Johnson were worth $17,452,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of JNJ. Americafirst Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter worth $101,000. Tuttle Tactical Management LLC acquired a new position in Johnson & Johnson during the second quarter worth $103,000. Lenox Wealth Management Inc. boosted its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the last quarter. Thomas J. Herzfeld Advisors Inc. boosted its position in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares during the last quarter. Finally, NCM Capital Management Group Inc. acquired a new position in Johnson & Johnson during the second quarter worth $127,000. 64.13% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.88% during mid-day trading on Monday, hitting $113.12. The stock had a trading volume of 4,765,296 shares. The stock has a market cap of $307.75 billion, a P/E ratio of 19.86 and a beta of 0.75. The company’s 50 day moving average price is $116.14 and its 200 day moving average price is $118.35. Johnson & Johnson has a 12-month low of $94.28 and a 12-month high of $126.07.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.66 by $0.02. The firm earned $17.80 billion during the quarter, compared to analysts’ expectations of $17.71 billion. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. Johnson & Johnson’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.49 EPS. Equities research analysts predict that Johnson & Johnson will post $6.72 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a $0.80 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.29. This represents a $3.20 annualized dividend and a yield of 2.80%. The ex-dividend date of this dividend is Friday, November 18th. Johnson & Johnson’s payout ratio is presently 56.64%.

WARNING: “Johnson & Johnson (JNJ) Shares Sold by Private Asset Management Inc.” was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/28/johnson-johnson-jnj-shares-sold-by-private-asset-management-inc.html.

JNJ has been the subject of a number of analyst reports. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price target for the company in a report on Monday, August 22nd. RBC Capital Markets set a $133.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Wednesday, November 9th. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, September 20th. Argus reiterated a “buy” rating and set a $145.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 21st. Finally, BTIG Research reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Thursday, August 25th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Hold” and an average target price of $121.02.

In other news, Director Charles Prince bought 875 shares of the stock in a transaction on Friday, October 21st. The stock was purchased at an average cost of $114.11 per share, with a total value of $99,846.25. Following the purchase, the director now owns 26,520 shares of the company’s stock, valued at $3,026,197.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.11% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.